• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world.

作者信息

Ogura Takashi, Kitamura Hideya

机构信息

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.

出版信息

Respirology. 2017 Aug;22(6):1051-1052. doi: 10.1111/resp.13059. Epub 2017 Apr 25.

DOI:10.1111/resp.13059
PMID:28440554
Abstract
摘要

相似文献

1
Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world.吡非尼酮或尼达尼布治疗肺纤维化在现实世界中的耐受性。
Respirology. 2017 Aug;22(6):1051-1052. doi: 10.1111/resp.13059. Epub 2017 Apr 25.
2
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.吡非尼酮和尼达尼布用于临床实践中的肺纤维化：耐受性和药物不良反应
Respirology. 2017 Aug;22(6):1171-1178. doi: 10.1111/resp.13024. Epub 2017 Mar 20.
3
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.尼达尼布和吡非尼酮治疗特发性肺纤维化的安全性和药代动力学。
Eur Respir J. 2015 May;45(5):1382-92. doi: 10.1183/09031936.00198013. Epub 2014 Dec 10.
4
Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.吡非尼酮与尼达尼布联合治疗特发性肺纤维化成功：一例报告
Respiration. 2016;91(4):327-32. doi: 10.1159/000444690. Epub 2016 Apr 14.
5
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.抗纤维化疗法在特发性肺纤维化患者中的耐受性和疗效：一项真实世界研究的结果。
Pulm Pharmacol Ther. 2024 Mar;84:102287. doi: 10.1016/j.pupt.2024.102287. Epub 2024 Jan 17.
6
Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.吡非尼酮和尼达尼布用于治疗特发性肺纤维化。
South Med J. 2017 Jun;110(6):393-398. doi: 10.14423/SMJ.0000000000000655.
7
Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.尼达尼布和吡非尼酮。用于特发性肺纤维化的新型抗纤维化治疗带来了希望，也引发了一些问题。
Am J Respir Crit Care Med. 2015 Feb 1;191(3):252-4. doi: 10.1164/rccm.201411-2044ED.
8
POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.观点：所有特发性肺纤维化患者，即使是那些有中度以上损伤的患者，都应该用尼达尼布或吡非尼酮治疗吗？应该。
Chest. 2016 Aug;150(2):273-5. doi: 10.1016/j.chest.2016.04.034. Epub 2016 Jun 9.
9
COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.反方观点：所有特发性肺纤维化患者，即使是那些有中度以上损伤的患者，都应该用尼达尼布或吡非尼酮治疗吗？不应该。
Chest. 2016 Aug;150(2):276-8. doi: 10.1016/j.chest.2016.04.036. Epub 2016 Jun 9.
10
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.特发性肺纤维化的用力肺活量——美国食品药品监督管理局对吡非尼酮和尼达尼布的审评
N Engl J Med. 2015 Mar 26;372(13):1189-91. doi: 10.1056/NEJMp1500526.

引用本文的文献

1
Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Wen-Yu-Jin against Pulmonary Fibrosis in a Mouse Model.基于网络药理学预测和分子对接的策略以发现温郁金对小鼠肺纤维化模型潜在药理机制的研究
Evid Based Complement Alternat Med. 2022 Feb 10;2022:7753508. doi: 10.1155/2022/7753508. eCollection 2022.